REG - Fusion Antibodies - Contract Win

Fusion AntibodiesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250828:nRSb9469Wa&default-theme=true

RNS Number : 9469W  Fusion Antibodies PLC  28 August 2025

28 August 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Contract Win

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that it has been selected to proceed with a new
humanisation project (the "Humanisation Project") under an existing Master
Service Agreement (the "Agreement") with a US based specialty division of a
global pharmaceutical company (the "Client").

 

While the Company expects to generate modest revenues from the Humanisation
Project, it demonstrates Fusion's ability to win contracts with 'Big Pharma'
companies. This is seen as a significant part of the Company's strategy not
only in reducing dependence on more volatile smaller clients, but also in
seeking to exploit its novel technologies such as OptiMAL®. Work in relation
to the Humanisation Project is expected to complete within the current
financial year.

 

Adrian Kinkaid, CEO of Fusion, said: "We are delighted to have been selected
to humanise a family of antibodies for our Client. It is particularly
gratifying that a client of this magnitude and with all the resources
available to it has selected Fusion to undertake this critical work.  We look
forward to continuing to work with our Client to fulfil our mission to bring
better antibodies to the clinic more rapidly. The Humanisation Project
highlights the world class reputation that Fusion has for delivering high
quality therapeutic antibodies.

 

"Whilst revenues from the new Humanisation Project will be relatively modest,
winning this contract provides recognition of our expertise in this highly
competitive market. We look forward building on the excellent relationship
with our Client."

 

Navigate to our Interactive Investor hub here:
https://investorhub.fusionantibodies.com/
(https://investorhub.fusionantibodies.com/) . Engage with us by asking
questions, watching video summaries and seeing what other shareholders have to
say.

 

Enquiries:

 

 Investor questions on this announcement
 We encourage all investors to share questions on this announcement via our      https://investorhub.fusionantibodies.com/s/b8d633
 investor hub                                                                    (https://investorhub.fusionantibodies.com/s/b8d633)

 Fusion Antibodies plc                                                           www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                                         Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                                      Tel: +44 (0) 207 186 9952

 Walbrook PR                             Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                     Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTPRMPTMTMTBRA